Roka Bio Q2 Revenues More than Double; Leerink Initiates Coverage with Outperform Rating | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm Roka Bioscience today reported that its second quarter revenues more than doubled year over year.

The Warren, NJ-based firm, which recently became a publicly traded company, reported revenues of $1.4 million for the three months ended June 30, up from $671,000 a year ago as the number of Atlas instruments placed with commercial customers and the commercial use of the platforms increased. As of the end of the quarter, Roka had 36 instrument placements, up from 21 in the year-ago period, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.